Idorsia's cookie policy provides information about what cookies are and how Idorsia's corporate website is utilizing them to improve your experience on our site. By closing this message, you consent to our use of cookies on this device in accordance with Idorsia's cookies policy unless you have taken actions to disable them. Learn more Accept Home About Idorsia Our responsibilities Investors Media Careers Contact Idorsia announces financial results for the first nine months of 2021 Investors: Results Day Center Facebook Idorsia Pharmaceuticals Ltd Tue Nov 23 12:00:05 CET 2021 Poor sleep patterns can develop out of the blue for no apparent reason, but in some cases, an underlying cause or trigger can be identified. Often, the impact on sleeping patterns is temporary and things improve when these external factors are no longer an issue. For some people, however, poor sleep can become an entrenched habit. Fear of not getting enough sleep adds to stress and tension, which can worsen sleep problems, leading to a vicious cycle. #sleep #insomnia #sleephealth Idorsia Pharmaceuticals Ltd Mon Nov 22 12:00:05 CET 2021 Insomnia is nowadays recognized as a condition that requires clinical attention, which is why we're focusing our efforts on helping patients that suffer from it. Did you know there are different types of insomnia? Have you ever suffered from any of these? #sleep #insomnia #sleephealth Idorsia Pharmaceuticals Ltd Fri Nov 19 12:00:11 CET 2021 "How would you describe your job to a 6 year old?". That's the question we asked some of our employees, who were eager to share their experience at Idorsia. Kevin Stauffer, our Corporate Communication Manager, takes the stage today to share his experience 🗣 Photos from Idorsia Pharmaceuticals Ltd's post Idorsia Pharmaceuticals Ltd Wed Nov 17 12:00:05 CET 2021 We have been sharing a little bit about what sleep is and how it functions. But on the flip side, do you know what insomnia is? Learn more about it today. #sleep #insomnia #sleephealth Idorsia Pharmaceuticals Ltd Mon Nov 15 12:00:11 CET 2021 You've probably heard the term REM sleep, and maybe its less famous counterpart, NREM before. But do you know what the differences between them are? Learn more today! #sleep #insomnia #sleephealth Photos from Idorsia Pharmaceuticals Ltd's post Twitter @Idorsia 14 days ago. On November 2nd, Idorsia chemists attended the @chemtogether career fair at @ETH. Almost 600 students attended and our booth was visited by many students across various fields of study. It was a pleasure meeting so many highly motivated young chemists, we'll be back next year! https://t.co/fMaf2xYZgf @Idorsia 23 days ago. Today, Idorsia announced that the company will advance our investigational therapy for systemic lupus erythematosus into Phase 3 development. Read more: https://t.co/Gcw5ujhatP https://t.co/NXhRzqWzLd @Idorsia 24 days ago. This week, Idorsia will be attending the @chemtogether careers event at the @ETH. Our team is looking forward to meeting students and PhD candidates who are passionate about chemistry and pharmaceutical studies and showing them what a career at Idorsia could mean for them! #stem https://t.co/74CPEdZh01 @Idorsia 25 days ago. Yesterday, Idorsia colleagues shared results from our phase 3 studies into our investigational #insomnia treatment at DGSM 2021 – did you catch any of our presentations? #sleepmedicine #insomnia #research @Idorsia 26 days ago. Learn about Idorsia’s investigational #insomnia treatment and the outcomes of our phase 3 studies into its efficacy and safety at DGSM 2021 today – Idorsia industry symposium at 12:30 CEST and poster presentations from 16:30 CEST Idorsia today The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. Find out more about Idorsia Idorsia People Idorsia’s success depends on its people. Find out more about the Idorsia team Target diseases Idorsia's development compounds target a number of different diseases. Find out more about our target diseases News View all 01 Nov 2021 Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus 27 Oct 2021 Johnson & Johnson partially converts its convertible loan 26 Oct 2021 Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway Events Event When Full-Year 2021 Financial Results reporting* February 8, 2022 Annual General Meeting of Shareholders April 14, 2022 First-Quarter 2022 Financial Results reporting* April 26, 2022 Half-Year 2022 Financial Results reporting* July 26, 2022 *We will be in a silent period for 10 days ahead of the financial reporting. Shareprice IDIA SIX Swiss Exchange At 17:20:28 CET 16.16 CHF -0.27 (-1.64 %) Further stock information Contact Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91 4123 Allschwil Switzerland +41 58 844 00 00 Contact us online How to get to us FOLLOW US: VIEWING OPTIONS This website is subject to the terms and conditions outlined in the legal and privacy statement. Last update: 26.10.2021 Legal & privacy statement|Site map|Cookie policy|Webmaster Copyright © 2021 Idorsia Pharmaceuticals Ltd